Seneca Therapeutics Reports Late Breaking Information on SVV-001 from the American Association for Cancer Research’s 2021 Annual Meeting

PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), announced today the poster presentation of Seneca Therapeutics’ abstract titled “Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV”. Key points from the presentation:

  1. SVV-001 demonstrates the ability to turn cold tumors hot;
  2. Intratumoral administration of SVV-001 in combination with a checkpoint inhibitor demonstrates up to six fold increase in anti-tumor response over SVV-001 alone or check point inhibitor therapy alone;
  3. SVV-001 specifically targets, infects and kills TEM8 positive cancer cells. No cell killing was observed in normal cells;
  4. RNA seq data confirm up regulation of genes known to stimulate an immune response;

A randomized Phase III clinical study comparing SVV-001 administered IT in combination with Opdivo and Yervoy compared to Opdivo and Yervoy alone in TEM8 positive neuroendocrine tumors and neuroendocrine carcinomas is planned to begin later in 2021. STI is also developing SVV-001 for intravenous use in TEM8 positive tumors as well as developing SVV-001 to deliver armed viruses to TEM8 positive tumor cells.

About Seneca Therapeutics

Seneca Therapeutics was founded by Dr. Paul Hallenbeck to develop SVV-001 related products. Seneca Therapeutics is also developing armed versions of SVV-001 to selectively express gene product(s) that are inserted into the genome of SVV-001 and create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

Contacts

Paul Hallenbeck

phallenbeck@senecatherapeutics.com

James Hussey

jhussey@senecatherapeutics.com
www.senecatherapeutics.com

Selección de Europa Rup

Denver Tech Center CPA Firm Recognized as Runner Up “Best Colorado Accounting Firm” by Colorado Biz Magazine

GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--Gomerdinger CPAs was awarded “runner up” in the 2022 Colorado Biz Magazine’s “Best of Colorado” Annual Readers’ Poll special supplement. CEO,...

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Missfresh Limited (MF)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 12, 2022 deadline to file a lead plaintiff motion in...

Leading manufacturer of engineered plastics becomes Viaflex

Raven Engineered Films adopts a new name after its acquisition by Industrial Opportunity Partners in April SIOUX FALLS, S.D.--(BUSINESS WIRE)--Today, Sioux Falls-based Raven Engineered Films...